-
1
-
-
33745936043
-
Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature
-
DOI 10.1016/j.clinthera.2006.06.003, PII S0149291806001391
-
Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT., Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006; 28: 801-831. (Pubitemid 44062692)
-
(2006)
Clinical Therapeutics
, vol.28
, Issue.6
, pp. 801-831
-
-
Ross, S.D.1
Elaine Allen, I.2
Henry, D.H.3
Seaman, C.4
Sercus, B.5
Goodnough, L.T.6
-
3
-
-
33750117840
-
Erythropoietin or darbepoetin for patients with cancer [serial online]
-
CD003407.
-
Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer [serial online]. Cochrane Database Syst Rev. 2006;(3):CD003407.
-
(2006)
Cochrane Database Syst Rev.
, Issue.3
-
-
Bohlius, J.1
Wilson, J.2
Seidenfeld, J.3
-
4
-
-
0037102975
-
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
-
DOI 10.1002/cncr.10763
-
Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95: 888-895. (Pubitemid 34839682)
-
(2002)
Cancer
, vol.95
, Issue.4
, pp. 888-895
-
-
Crawford, J.1
Cella, D.2
Cleeland, C.S.3
Cremieux, P.-Y.4
Demetri, G.D.5
Sarokhan, B.J.6
Slavin, M.B.7
Glaspy, J.A.8
-
5
-
-
65449117261
-
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer a meta-analysis of randomized trials
-
Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer a meta-analysis of randomized trials. Lancet. 2009; 373: 1532-1542.
-
(2009)
Lancet.
, vol.373
, pp. 1532-1542
-
-
Bohlius, J.1
Schmidlin, K.2
Brillant, C.3
-
6
-
-
75549086280
-
Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes
-
Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010; 102: 301-315.
-
(2010)
Br J Cancer.
, vol.102
, pp. 301-315
-
-
Glaspy, J.1
Crawford, J.2
Vansteenkiste, J.3
-
7
-
-
57449115332
-
Tumor progression associated with erythropoiesis-stimulating agents
-
Newland AM, Black CD., Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother. 2008; 42: 1865-1870.
-
(2008)
Ann Pharmacother.
, vol.42
, pp. 1865-1870
-
-
Newland, A.M.1
Black, C.D.2
-
8
-
-
40349103260
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
-
DOI 10.1001/jama.299.8.914
-
Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299: 914-924. (Pubitemid 351397066)
-
(2008)
JAMA - Journal of the American Medical Association
, vol.299
, Issue.8
, pp. 914-924
-
-
Bennett, C.L.1
Silver, S.M.2
Djulbegovic, B.3
Samaras, A.T.4
Blau, C.A.5
Gleason, K.J.6
Barnato, S.E.7
Elverman, K.M.8
Courtney, D.M.9
McKoy, J.M.10
Edwards, B.J.11
Tigue, C.C.12
Raisch, D.W.13
Yarnold, P.R.14
Dorr, D.A.15
Kuzel, T.M.16
Tallman, M.S.17
Trifilio, S.M.18
West, D.P.19
Lai, S.Y.20
Henke, M.21
more..
-
9
-
-
67650874081
-
Cancer statistics 2009
-
Jemal A, Siegel R, Ward E, Yongping H, Xu J, Thun MJ., Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 225-249.
-
(2009)
CA Cancer J Clin.
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Yongping, H.4
Xu, J.5
Thun, M.J.6
-
10
-
-
63049115790
-
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup
-
Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27: 1419-1425.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 1419-1425
-
-
Bookman, M.A.1
Brady, M.F.2
McGuire, W.P.3
-
11
-
-
33847700189
-
The role of epoetin beta in the treatment of anaemia in patients with gynaecological malignancies
-
Cornes P, Boiangiu I., The role of epoetin beta in the treatment of anemia in patients with gynaecological malignancies. Anticancer Res. 2007; 27 (IB): 513-522. (Pubitemid 46379710)
-
(2007)
Anticancer Research
, vol.27
, Issue.1 B
, pp. 513-522
-
-
Cornes, P.1
Boiangiu, I.2
-
13
-
-
0142186283
-
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial
-
DOI 10.1016/S0140-6736(03)14567-9
-
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 2003; 362: 1255-1260. (Pubitemid 37324251)
-
(2003)
Lancet
, vol.362
, Issue.9392
, pp. 1255-1260
-
-
Henke, M.1
Laszig, R.2
Rube, C.3
Schafer, U.4
Haase, K.-D.5
Schilcher, B.6
Mose, S.7
Beer, K.T.8
Burger, U.9
Dougherty, C.10
Frommhold, H.11
-
14
-
-
35448992197
-
Radiotherapy With or Without Erythropoietin for Anemic Patients With Head and Neck Cancer: A Randomized Trial of the Radiation Therapy Oncology Group (RTOG 99-03)
-
DOI 10.1016/j.ijrobp.2007.04.063, PII S0360301607007572
-
Machtay M, Pajak TF, Suntharalingram M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007; 69: 1008-1017. (Pubitemid 47625834)
-
(2007)
International Journal of Radiation Oncology Biology Physics
, vol.69
, Issue.4
, pp. 1008-1017
-
-
Machtay, M.1
Pajak, T.F.2
Suntharalingam, M.3
Shenouda, G.4
Hershock, D.5
Stripp, D.C.6
Cmelak, A.J.7
Schulsinger, A.8
Fu, K.K.9
-
15
-
-
24944454286
-
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
-
Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23: 5960-5972.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 5960-5972
-
-
Leyland-Jones, B.1
Semiglazov, V.2
Pawlicki, M.3
-
16
-
-
0037151364
-
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
-
Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94: 1211-1220. (Pubitemid 34993871)
-
(2002)
Journal of the National Cancer Institute
, vol.94
, Issue.16
, pp. 1211-1220
-
-
Vansteenkiste, J.1
Pirker, R.2
Massuti, B.3
Barata, F.4
Font, A.5
Fiegl, M.6
Siena, S.7
Gateley, J.8
Tomita, D.9
Colowick, A.B.10
Musil, J.11
-
17
-
-
0035367087
-
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
-
Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19: 2865-2874. (Pubitemid 32538196)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.11
, pp. 2865-2874
-
-
Littlewood, T.J.1
Bajetta, E.2
Nortier, J.W.R.3
Vercammen, E.4
Rapoport, B.5
-
18
-
-
21044442522
-
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
-
DOI 10.1200/JCO.2004.10.020
-
Witzig TE, Silberstein PT, Loprinzi C, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005; 23: 2606-2617. (Pubitemid 46179449)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.12
, pp. 2606-2617
-
-
Witzig, T.E.1
Silberstein, P.T.2
Loprinzi, C.L.3
Sloan, J.A.4
Novotny, P.J.5
Mailliard, J.A.6
Rowland, K.M.7
Alberts, S.R.8
Krook, J.E.9
Levitt, R.10
Morton, R.F.11
-
19
-
-
18444398661
-
Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy
-
DOI 10.1200/JCO.2004.12.027
-
Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005; 23: 2597-2605. (Pubitemid 46179448)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.12
, pp. 2597-2605
-
-
Chang, J.1
Couture, F.2
Young, S.3
McWatters, K.-L.4
Lau, C.Y.5
-
20
-
-
22144472209
-
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial
-
DOI 10.1016/j.ejca.2005.03.024, PII S0959804905003333
-
Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level, and survival during platinum-based chemotherapy: results of a multicenter randomized controlled trial. Eur J Cancer. 2005; 41: 1560-1569. (Pubitemid 40981838)
-
(2005)
European Journal of Cancer
, vol.41
, Issue.11
, pp. 1560-1569
-
-
Savonije, J.H.1
Van Groeningen, C.J.2
Van Bochove, A.3
Honkoop, A.H.4
Van Felius, C.L.5
Wormhoudt, L.W.6
Giaccone, G.7
-
21
-
-
33749133212
-
Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation
-
DOI 10.1111/j.1525-1438.2006.00709.x
-
Temkin SM, Hellmann M, Serur E, Lee Y-C, Abulafia O., Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer. 2006; 16: 1855-1861. (Pubitemid 44470046)
-
(2006)
International Journal of Gynecological Cancer
, vol.16
, Issue.5
, pp. 1855-1861
-
-
Temkin, S.M.1
Hellmann, M.2
Serur, E.3
Lee, Y.-C.4
Abulafia, O.5
-
22
-
-
38649128164
-
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin versus above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
-
Thomas G, Ali S, Hoebers FJP, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin versus above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008; 108: 317-325.
-
(2008)
Gynecol Oncol.
, vol.108
, pp. 317-325
-
-
Thomas, G.1
Ali, S.2
Hoebers, F.J.P.3
-
23
-
-
33645750210
-
Epoetin alfa in platinum-treated ovarian cancer patients: Results of a multinational, multicentre, randomised trial
-
EPO-INT-45 Study Group.
-
Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P,; EPO-INT-45 Study Group. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer. 2006; 94: 947-954.
-
(2006)
Br J Cancer.
, vol.94
, pp. 947-954
-
-
Wilkinson, P.M.1
Antonopoulos, M.2
Lahousen, M.3
Lind, M.4
Kosmidis, P.5
-
24
-
-
77953629597
-
Absence of functional EpoR expression in human tumor cell lines
-
Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010; 115: 4254-4263.
-
(2010)
Blood.
, vol.115
, pp. 4254-4263
-
-
Swift, S.1
Ellison, A.R.2
Kassner, P.3
-
25
-
-
77952172809
-
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells
-
Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010; 115: 4264-4272.
-
(2010)
Blood.
, vol.115
, pp. 4264-4272
-
-
Sinclair, A.M.1
Coxon, A.2
McCaffery, I.3
-
26
-
-
50949087648
-
Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor bearing mice by enhancing angiogenesis
-
Okazaki T, Ebihara S, Asada M, et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor bearing mice by enhancing angiogenesis. Neoplasia. 2008; 10: 932-939.
-
(2008)
Neoplasia.
, vol.10
, pp. 932-939
-
-
Okazaki, T.1
Ebihara, S.2
Asada, M.3
|